Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew Plc    SN.   GB0009223206


Real-time Estimate Quote. Real-time Estimate CHI-X - 01/26 11:30:00 am
1640.25 GBX   +1.82%
01/25SETTING THE STAGE : Court Sets Oral Argument In Arthrex Cases
01/19European ADRs Move Higher in Tuesday Trading
01/12European ADRs Move Higher in Tuesday Trading
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith & Nephew : New data shows Smith+Nephew's NOVOSTITCH Meniscal Repair Systems achieve 82.6% success rate for difficult to repair horizontal cleavage tears

11/18/2020 | 09:44am EST

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is pleased to announce the conclusion of and successful two-year follow-up results from the STITCH Study for its novel NOVOSTITCH Meniscal Repair Systems.

The two-year results make a compelling case for surgeons to consider repairing the meniscus versus removing it.

The STITCH Study is the first of its kind, prospective clinical trial to evaluate the effectiveness of repairing Horizontal Cleavage Tears (HCTs), one of the most common meniscal tears.2 Of the 1.2 million tears that occur annually in the US, nearly 80% are treated by partial resection,3,4 also known as meniscectomy, which may put the patient at risk for adverse changes to the knee joint by leaving them open to osteoarthritis or total knee replacement later in life.5, 6


Dave Snyder

Tel: (+1) 978-749-1440

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 16,000+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.9 billion in 2018. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about SMITH & NEPHEW PLC
01/25SETTING THE STAGE : Court Sets Oral Argument In Arthrex Cases
01/19European ADRs Move Higher in Tuesday Trading
01/12European ADRs Move Higher in Tuesday Trading
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
01/11European ADRs Move Sharply Lower in Monday Trading
01/11SMITH & NEPHEW : Warns of Revenue, Margin Hit for 2020
01/11SMITH & NEPHEW : Expects Q4, FY20 Revenue Drop On Lower Sales, Volumes Amid COVI..
01/11SMITH & NEPHEW PLC : 4th quarter results
01/06SMITH & NEPHEW PLC : Nomination
01/05SMITH & NEPHEW : Arthrex's Initial Merits Brief – Making The Case For Pate..
More news
Financials (USD)
Sales 2020 4 582 M - -
Net income 2020 373 M - -
Net Debt 2020 1 650 M - -
P/E ratio 2020 54,6x
Yield 2020 1,29%
Capitalization 19 285 M 19 251 M -
EV / Sales 2020 4,57x
EV / Sales 2021 3,87x
Nbr of Employees 17 500
Free-Float 98,7%
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 23,48 $
Last Close Price 22,03 $
Spread / Highest target 23,9%
Spread / Average Target 6,56%
Spread / Lowest Target -18,0%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations & Business Services
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors